Aduro BioTech Inc (NASDAQ:ADRO) insider Stephen T. Isaacs sold 24,143 shares of the stock in a transaction dated Thursday, September 13th. The shares were sold at an average price of $6.50, for a total transaction of $156,929.50. Following the completion of the sale, the insider now owns 356,996 shares of the company’s stock, valued at $2,320,474. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of ADRO traded up $0.28 during mid-day trading on Friday, reaching $6.75. The stock had a trading volume of 257,329 shares, compared to its average volume of 282,302. Aduro BioTech Inc has a 52-week low of $5.10 and a 52-week high of $11.55. The firm has a market capitalization of $549.47 million, a P/E ratio of -4.75 and a beta of 2.23.

Aduro BioTech (NASDAQ:ADRO) last announced its quarterly earnings data on Wednesday, August 1st. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.02. The firm had revenue of $2.64 million during the quarter, compared to analyst estimates of $3.74 million. Aduro BioTech had a negative net margin of 574.11% and a negative return on equity of 44.97%. equities analysts anticipate that Aduro BioTech Inc will post -1.25 EPS for the current year.

A number of equities research analysts recently issued reports on the stock. BidaskClub lowered shares of Aduro BioTech from a “hold” rating to a “sell” rating in a report on Wednesday, July 25th. ValuEngine raised shares of Aduro BioTech from a “strong sell” rating to a “sell” rating in a report on Thursday, August 30th. Canaccord Genuity reissued a “buy” rating and issued a $30.00 price objective on shares of Aduro BioTech in a report on Thursday, August 2nd. Bank of America dropped their price objective on shares of Aduro BioTech from $8.00 to $6.00 and set an “underperform” rating for the company in a report on Thursday, August 2nd. Finally, HC Wainwright set a $10.00 price objective on shares of Aduro BioTech and gave the company a “buy” rating in a report on Thursday, August 2nd. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $13.67.

A number of hedge funds have recently made changes to their positions in ADRO. Aquilo Capital Management LLC purchased a new position in Aduro BioTech during the second quarter worth about $14,055,000. Citadel Advisors LLC boosted its stake in Aduro BioTech by 958.5% during the second quarter. Citadel Advisors LLC now owns 1,590,832 shares of the biotechnology company’s stock worth $11,136,000 after buying an additional 1,440,546 shares during the period. Baillie Gifford & Co. boosted its stake in Aduro BioTech by 69.6% during the second quarter. Baillie Gifford & Co. now owns 2,810,508 shares of the biotechnology company’s stock worth $19,673,000 after buying an additional 1,153,771 shares during the period. BlackRock Inc. boosted its stake in Aduro BioTech by 32.5% during the second quarter. BlackRock Inc. now owns 4,706,526 shares of the biotechnology company’s stock worth $32,945,000 after buying an additional 1,153,301 shares during the period. Finally, Millennium Management LLC boosted its stake in Aduro BioTech by 329.7% during the first quarter. Millennium Management LLC now owns 1,282,347 shares of the biotechnology company’s stock worth $11,926,000 after buying an additional 983,906 shares during the period. 49.01% of the stock is owned by institutional investors.

About Aduro BioTech

Aduro BioTech, Inc, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.

Recommended Story: Penny Stocks, What You Need To Know

Insider Buying and Selling by Quarter for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.